Case Reports in Oncology · 2018 · 13 citations · 15 references
MedicineOncologyPharmacologyChemotherapyMedical OncologyMetastasisCancer ImmunotherapyCombination ChemotherapyImmunotherapy For Thoracic MalignanciesLung MetastasisMalignant NeoplasmsMetastatic Disease TreatmentChemotherapy For Pleural TumorsNanoparticle-based ChemotherapyProspective Case StudyPulmonary NeoplasmsRecurrenceSecond-line ChemotherapySecond-line Immunotherapy
Pulmonary pleomorphic carcinoma (PPC) has a poor prognosis due to the poor results of treatment with systemic chemotherapy. We report the case of a 73-year-old woman with PPC who showed a favorable response to nivolumab. As first-line treatment for postoperative recurrence, she received carboplatin and nanoparticle albumin-bound paclitaxel. However, 12 months later, a new metastatic lymph node appeared. Nivolumab was administered as second-line treatment, and the patient showed a favorable prolonged response. The effects of treatment of PPC with nivolumab seem promising. The results of a future prospective study are expected to identify indicators for the treatment of PPC.
15
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
E.E. Vokes, Neal Ready, Enriqueta Felip et al. · Annals of Oncology · 2018 · 469 citations · Full text
Medicine, Oncology, Pharmacology +17